Rating and price target: Outperform rating with a $1.40 price target Implied upside: approximately 493% above the $0.236 closing price on Tuesday, October 27, 2026 Valuation basis: 1.42 times Noble's 2027 revenue estimate, a discount to the 1.5 times peer average Record fourth quarter: Noble forecasts fourth-quarter 2026 revenue of $35.7 million and adjusted EBITDA of $6.4 million Accelerating revenue growth: Noble forecasts revenue of $90.0 million in 2026, up approximately 38%, rising 46% to $131.2 million in 2027 Positive adjusted EBITDA in 2026: Noble forecasts adjusted EBITDA of $3.9 million Positive free cash flow in 2027: Noble forecasts free cash flow of $10.0 million CHICAGO, IL / ACCESS Newswire / October 28, 2026 / Cosmos Health Inc. (" Cosmos Health " or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today announced that Noble Capital Markets ("Noble") has initiated company-sponsored equity research coverage on the Company with an Outperform rating and a price target of $1.40 per share. The research report, authored by Noble Capital Markets Senior Research Analyst Michael Kupinski , is available on Channelchek , along with the latest news, market data, and additional information on Cosmos Health (COSM). Management encourages investors to review the report and visit Channelchek for ongoing coverage and updates. The report, titled "Building a Higher-Margin Healthcare Platform," includes the following key estimates and conclusions: Rating and price target: Outperform rating with a $1.40 price target, approximately 493% above the $0.236 closing price on Tuesday, October 27, 2026 Valuation: the price target is based on 1.42 times Noble's 2027 revenue estimate of $131.2 million , implying an enterprise value of approximately $186.3 million , a modest discount to the peer group average of 1.5 times Revenue growth: Noble forecasts revenue of $90.0 million in 2026, up approximately 38%, rising to $131.2 million in 2027 and $160.8 million in 2028 Record fourth quarter: Noble forecasts fourth-quarter 2026 revenue of $35.7 million , adjusted EBITDA of $6.4 million and gross margin of 40.1% Margin expansion: Noble expects consolidated gross margin to expand from 12.1% in 2025 to 31.5% in 2028 Earnings growth: Noble forecasts adjusted EBITDA turning positive at $3.9 million in 2026 and increasing to $16.7 million in 2027 and $27.4 million in 2028 Cash flow: Noble forecasts free cash flow turning positive at $10.0 million in 2027 and increasing to $16.8 million in 2028 Noble identifies the Company's proprietary products, led by its U.S . direct-to-consumer business, and Cana Laboratories' contract manufacturing operations as the principal drivers of its shift toward higher-margin revenue, which Noble expects to grow from approximately 25% of total revenue in 2026 to approximately 44% in 2028. The views, estimates and price target in the report are those of Noble Capital Markets . Greg Siokas , CEO of Cosmos Health , stated: "We are delighted to welcome Noble's coverage of Cosmos Health . For years, we have been building a vertically integrated healthcare platform, and today that platform is entering its most exciting phase, with growth coming from our proprietary brands, our expanding manufacturing operations and our rapidly scaling U.S . subscription business. "Coverage from a firm with Noble's track record helps a much broader investor audience discover the transformation underway at Cosmos Health . We are energized by the opportunity ahead, and we are determined to keep executing and delivering results that create lasting value for our shareholders." About Noble Capital Markets Established in 1984, Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. Noble delivers middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports. About Channelchek Noble launched www.channelchek.com in 2018 - an investor community dedicated exclusively to public emerging growth companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 7,000 public emerging growth companies are listed on the site, and content including equity research, webcasts, and industry articles. About Cosmos Health Inc. Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (